★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets FDA Could Approve First CRISPR Treatment in US Before Year End, Marking New Territory for Gene Editing Tech CRISPR gene editing therapies took a big step toward commercialization in the United States last week, as the FDA laid…McAlinden Research PartnersJune 13, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets More FDA Approvals Arise in Gene Editing Space, Renewed VC Rounds Begin to Ramp Up Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…McAlinden Research PartnersMay 25, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene Editing FDA Approvals for Genetic Medicines Speed Ahead Despite Recent Setbacks in Base Editing Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…McAlinden Research PartnersDecember 8, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingⓁ PharmaceuticalsMarkets Pharma Fires Up More M&A Deals in Genetic Medicine as First CRISPR Drug Moves Closer to Commercialization Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…McAlinden Research PartnersOctober 19, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets CRISPR Tech Closes in on First FDA Approval, New Treatment Methods Continue to Emerge The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…McAlinden Research PartnersSeptember 29, 2022
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarkets New Genomic Breakthroughs Could Spark a CRISPR Comeback and Renewed M&A Activity in Biotech Despite a prolonged sell-off in biotech stocks, the development of genomic medicine has continued apace. For just the third time,…McAlinden Research PartnersMay 23, 2022
★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Gene Editing Firms Expand Potential Treatments by Shrinking Proteins, Focusing on RNA Research Research into CRISPR gene editing technology continues to expand the amount of potential applications, while shrinking the actual size of proteins…McAlinden Research PartnersSeptember 8, 2021
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & Healthcare Gene Editing Stocks Surge in the Wake of Strong Clinical Data, Closing out an Explosive 2020 A wealth of new data from several leading genomics firms have launched stocks in the sector higher in the fourth…McAlinden Research PartnersDecember 22, 2020
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & Healthcare Gene Editing Trials See New Success in Neurology, Optometry, and Obesity Treatment New developments in advanced methods of CRISPR, particularly in base and prime editing, continue to propel the popularity of the…McAlinden Research PartnersSeptember 1, 2020
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & Healthcare CRISPR Cures Blood Disorders and Scrambles Coronavirus Treatments utilizing Clustered Regularly Interspace Short Palindromic Repeats (CRISPR), continue to rack up clinical success. The latest research on blood…McAlinden Research PartnersJune 16, 2020